Lineage Cell Therapeutics Inc
F:BT3
Shareholder Yield
Current shareholder yield for BT3 is hidden .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Peers Comparison
Shareholder Yield
Buybacks
Buyback Yield measures how much a company reduces its outstanding shares through repurchases, expressed as a percentage.
This metric directly reflects the company’s efforts to return value to shareholders. By reducing the number of shares, buybacks can increase earnings per share and potentially boost the stock's price.
Peers Comparison
Buybacks
Debt Paydown
Debt Paydown Yield measures the amount of debt a company repays within a specific period, shown as a percentage of its market capitalization.
This metric indicates how the company is using its capital to decrease financial liabilities, which can strengthen its financial health and potentially enhance shareholder value.
Peers Comparison
Debt Paydown
Price Appreciation
BT3 Price
Lineage Cell Therapeutics Inc
| Average Annual Return | -30.33% |
| Standard Deviation of Annual Returns | 23.67% |
| Max Drawdown | -87% |
| Market Capitalization | 410m EUR |
| Shares Outstanding | 188 754 000 |
| Percentage of Shares Shorted |
N/A
|
BT3 Return Decomposition
Main factors of price return
Stock Splits
BT3's latest stock split occurred on Nov 25, 2019
The company executed a 1-for-3 stock split, meaning that for every 3 shares held, investors received 1 new share.
Before the split, BT3 traded at 0.79 per share. Afterward, the share price was about 0.775.
The adjusted shares began trading on Nov 25, 2019. This was the only stock split in BT3's history.
